Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Roland Schott"'
Autor:
Alexis B. Cortot, David Planchard, Hélène Doubre, Bénédicte Mastroianni, Sylvestre Le Moulec, Florian Guisier, Lionel Falchero, Jennifer Arrondeau, Aldo Renault, Isabelle Monnet, Laurent Greillier, Marie Wislez, L. Gérinière, Jean Bernard Auliac, Chantal Decroisette, Maurice Pérol, Eric Pichon, Catherine Daniel, Christos Chouaid, Roland Schott
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
International audience; Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimert
Autor:
Isabelle Martel-Laffay, Alain Vergnenegre, Radj Gervais, Paul Lesueur, Christos Chouaid, Alexandre Escande, Roland Schott, M. Kissel, Chrystel Locher
Publikováno v:
Expert Review of Anticancer Therapy. 18:1159-1165
Cisplatin-based chemotherapy administered concomitantly to thoracic radiotherapy is the treatment recommended by the European guidelines for fit patients with unresectable stage III non-small cell lung cancer (NSCLC). Cisplatin may be combined with e
Autor:
Marie Wislez, David Planchard, Eric Dansin, Christos Chouaid, Renaud Descourt, Loick Galland, Bertrand Mennecier, Roland Schott, Maurice Pérol, G. Rousseau-Bussac, Jean-Bernard Auliac, Jennifer Arrondeau, Florian Guisier, Alexis B. Cortot, Pascal Do
Publikováno v:
Lung Cancer
Lung Cancer, Elsevier, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩
Lung Cancer, Elsevier, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩
Objectives Brigatinib is a next-generation ALK inhibitor initially developed in ALK-positive NSCLC pretreated with crizotinib. Materials and Methods This retrospective multicentric study analyzed ALK-positive advanced NSCLC patients pretreated with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3d651be5835b88ec8bc90d8a53349e6
https://hal.archives-ouvertes.fr/hal-02570654
https://hal.archives-ouvertes.fr/hal-02570654
Autor:
Christos Chouaid, Roland Schott, Jaafar Bennouna, Franck Bonnetain, Lionel Falchero, Mathieu Coudert, Béchir Ben Hadj Yahia
Publikováno v:
Oncology. 94:55-64
Objectives: The aim of this study was to describe the characteristics of patients receiving bevacizumab plus first-line metastatic chemotherapy for non-squamous advanced non-small cell lung cancer (aNSCLC), with or without brain metastases, in routin
Autor:
Christelle Clément-Duchêne, Xavier Quantin, Anne-Marie Ruppert, Radj Gervais, Sylvestre Le Moulec, Benjamin Besse, Gilles Robinet, Julien Mazieres, Jean Trédaniel, Christos Chouaid, Roland Schott, Anne-Catherine Madroszyk, Fabrice Barlesi, Hervé Lena, Maurice Pérol, Denis Moro-Sibilot, Henri Berard, Jean-Charles Soria, Pierre Jean Souquet, Hélène Senellart, Eric Dansin, Lionel Falchero
Publikováno v:
Clinical Cancer Research. 21:1896-1903
Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non–small cell lung cancer (NSCLC) and asymptomatic untreated brain metas
Autor:
Stéphanie Dehette, Vincent Le Pennec, Eric Dansin, Francis Martin, Cécile Dujon, Jacky Crequit, Armelle Lavolé, Bénédicte Precheur-Agulhon, Christos Chouaid, Roland Schott, Alain Rivière, Elizabeth Fabre, Delphine Lerouge, Eric Lartigau, Gérard Zalcman, Pierre Fournel
Publikováno v:
BMC Cancer
Background Concomitant platinum-based chemotherapy and radiotherapy (CT-RT) is the recommended treatment for unresectable locally advanced stage III non-small cell lung cancer (NSCLC). We conducted a phase II study to evaluate the efficacy and safety